In preclinical models, TN- and TCM-derived CAR-Ts outperformed their TEM-derived counterparts [56,58], while CD30-CAR-Ts generated from TSCM-like cells presented long-term persistence and fully eradicated the tumor, even after tumor rechallenge [59]. This evidence concerns the gene TNFRSF8 and neoplasm.